MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EOLS stock logo

EOLS

Evolus, Inc.

$4.03
-0.28
 (-6.5%)
Exchange:  NASDAQ
Market Cap:  262.192M
Shares Outstanding:  18.593M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  David Moatazedi
Full Time Employees:  372
Address: 
520 Newport Center Drive
Newport Beach
CA
92660
US
Website:  https://www.evolus.com
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/07 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue202,085266,274297,176
Gross Profit140,526182,304192,762
EBITDA-41,810-25,001-28,857
Operating Income-49,233-34,411-37,600
Net Income-61,685-50,420-51,641

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets188,998232,569225,868
Total Liabilities209,687227,047248,974
Total Stockholders Equity-20,6895,522-23,106
Total Debt126,546129,979154,996
Cash and Cash Equivalents62,83886,95253,826

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-34,008-17,999-42,265
Capital Expenditure-1,627-1,472-3,441
Free Cash Flow-35,635-19,471-45,706
Net Income-61,685-50,420-51,641
Net Change in Cash8,91624,114-33,126

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)582,711.024Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)602,265.177Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)593,117.400Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)131,173.713Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)135,575.536Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)133,516.286Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)103,317.376Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)107,848.902Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)105,729.161Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)510,642.420Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)527,778.152Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)519,761.755Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.640Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.670Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.600Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
266.274M  ?P/S
 (TTM)
: 
1.03
?Net Income
 (TTM)
: 
-50420000  ?P/E
 (TTM)
: 
-5.86
?Enterprise Value
 (TTM)
: 
406.301M  ?EV/FCF
 (TTM)
: 
-8.39
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
2.68  ?ROIC
 (TTM)
: 
-0.24
?Net Debt
 (TTM)
: 
43.027M  ?Debt/Equity
 (TTM)
: 
-6.71
?P/B
 (TTM)
: 
-13.09  ?Current Ratio
 (TTM)
: 
1.9

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
21.21Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate EOLS Intrinsic Value

Common questions about EOLS valuation

Is Evolus, Inc. (EOLS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Evolus, Inc. (EOLS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EOLS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EOLS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EOLS’s P/E ratio?

You can see EOLS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EOLS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EOLS a good long-term investment?

Whether EOLS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

EOLS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-6.5
MARKETSnap

Trading Metrics:

Open: 4.18   Previous Close: 4.31
Day Low: 3.99   Day High: 4.18
Year Low: 3.86   Year High: 12.28
Price Avg 50: 4.63   Price Avg 200: 6.6
Volume: 838116   Average Volume: 1.114M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13-02-2026 16:05
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
17-03-2026 02:32
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
04-03-2026 02:42
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
03-03-2026 19:06
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
09-01-2026 08:30
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read